Numerate raises $8M from Atlas, Lilly; InVivo slashes staff; J&J Innovation inks Dana-Farber pact;

@FierceBiotech: Merck targets Alzheimer's in $526M collaboration on new cognitive treatment. More | Follow @FierceBiotech

@JohnCFierce: Biotech star Bosley takes the helm at Editas. Item | Follow @JohnCFierce

@DamianFierce: Shire's Ornskov isn't sweating AbbVie, keeping up with the World Cup. Story (The Danish Dynamite didn't qualify.) | Follow @DamianFierce

@EmilyMFierce: Mersana partners with EMD Serono to advance ADC platform. Article | Follow @EmilyMFierce

San Bruno, CA-based Numerate, a company working on machine-learning algorithms for drug discovery, raised $8 million in new financing, which was provided by Atlas Venture and Lilly Ventures. "Their investment recognizes the success of our novel drug design platform in solving key problems of small molecule drug discovery and will enable us to advance our lead programs in metabolic, cardiovascular and neurodegenerative diseases," says CEO Guido Lanza. "In metabolic disease, we are targeting the free fatty acid receptors to address diabetes, obesity and related co-morbidities, while in cardiovascular disease we are targeting the Ryanodine receptor 2 to discover improved drugs for heart failure and arrhythmia." Release

Cambridge, MA-based InVivo Therapeutics, a stem cell company, is laying off 14 staffers--or 28% of its work force--in a restructuring. Release

The busy dealmaking team at J&J Innovation inked a collaboration on immuno-oncology related to lung cancer with the Dana-Farber Cancer Institute. Release

Ireland's Prothena plans to raise $100 million through the sale of shares. Release

Alexion Pharmaceuticals and Cincinnati Children's Hospital Medical Center forged a collaboration and fund for new research on rare pediatric diseases. Release

Medical Device News

@FierceMedDev: New fibroid-removal device provides less invasive alternative. News | Follow @FierceMedDev

@StacyALawrence: Apple, Google stalk wearable med tech with glucose monitoring up first. More | Follow @StacyALawrence

@MichaelGFierce: Sinus drug delivery startup Intersect ENT files for $80 million IPO. Story via Silicon Valley Business Journal | Follow @MichaelGFierce

@EmilyWFierce: California's high court rules that large retailers don't need to keep external defibrillators on hand for customers. Story via LA Times | Follow @EmilyWFierce

> Philips launches image-guided neurology surgical tech in Europe. More

> Medtronic rebuffed by SCOTUS in pain-pump lawsuit. Story

Pharma News

@FiercePharma: Drugmakers in India trapped between price caps and shortage rules. More | Follow @FiercePharma

@TracyStaton: Here's @JohnCFierce's take on the Vertex VX-809/Kalydeco PhIII, including interview with CEO Jeff Leiden. Story | Follow @TracyStaton

@EricPFierce: Abbott, in Russia since 1978, knows the game, buys Veropharm to establish local production credentials. News | Follow @EricPFierce

@CarlyHFierce: Have YOU checked out the list of 15 Highest-Paid Biopharma CEOs of 2013? Report | Follow @CarlyHFierce

> ThromboGenics doesn't want a deal. It wants a marketing partner for floundering Jetrea. Story

> Abbott bulks up in Russia with $495M deal for Veropharm. More

Biotech Research News

> UC San Diego to lead $2M statewide brain research project. More

> NIH awards U. of Buffalo $4.4M to repurpose old antibiotics. Story

> Novartis MS drug Gilenya could relieve painful side effect of chemo. Article

> UPenn team IDs potential target for treating Type 1 diabetes. News

> Mersana partners with EMD Serono to advance ADC platform. Report

Pharma Manufacturing News

> Carlyle buys Japanese contract manufacturer Sunsho. More

> West Pharmacuetical readies its first India injectables packaging plant. Article

> Abbott gets local production cred with deal to buy Russia's Veropharm. News

> Drugmakers in India trapped between price caps and shortage rules. Report

> Aesica plant in Italy responds as China's track and trace rules come into play. Story

> GSK vaccine plant in Texas about a year away. Item

Suggested Articles

A new, late-phase analysis of the cholesterol-lowering inclisiran showed that it was able to cut LDL levels by 51% after nearly a year-and-a-half.

The data was highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.